Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sotorasib + bevacizumab-awwb + chemotherapy
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral (sotorasib), Intravenous (bevacizumab-awwb, Chemotherapy)
01
Overview
Sotorasib + bevacizumab-awwb + chemotherapy is an investigational combination regimen used in clinical trials for the treatment of advanced solid tumors, particularly metastatic colorectal cancer harboring KRAS G12C mutations. Sotorasib is a small molecule inhibitor targeting the KRAS G12C mutation, thus blocking downstream cell proliferation signals. Bevacizumab-awwb (MVASI) is a biosimilar of bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), suppressing angiogenesis. Chemotherapy regimens typically include agents like FOLFIRI (5-fluorouracil, leucovorin, and irinotecan), which damage DNA or inhibit cell division. The purpose of combining these modalities is to synergistically target tumor growth at genetic, signaling, vascular, and proliferative levels[2][6][7].
- Brand names
- MVASI
- Other names
- sotorasibbevacizumab-awwbMVASILumakraschemotherapy
02
Targets
VEGFA (Vascular endothelial growth factor A)TOP1 (DNA Topoisomerase I)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)TS (Thymidylate synthase)
Beyond the preview
Go deeper on sotorasib + bevacizumab-awwb + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sotorasib + bevacizumab-awwb + chemotherapy.